Blocking CXCR2 with SB225002 has proved to inhibit tumor progression in breast cancer [165], ovarian cancer [166], acute myeloid leukemia [167], and nasopharyngeal carcinoma [168]. This evidence concerns the gene CXCR2 and ovarian carcinoma.